| Autor: |
Fa A; School of Medicine, LSU Health Sciences Center-New Orleans, New Orleans, LA 70112, USA., Danos DM; School of Public Health, LSU Health Science Center-New Orleans, New Orleans, LA 70112, USA., Maniscalco L; Louisiana Tumor Registry, School of Public Health, LSU Health Science Center-New Orleans, New Orleans, LA 70112, USA., Yi Y; Louisiana Tumor Registry, School of Public Health, LSU Health Science Center-New Orleans, New Orleans, LA 70112, USA., Wu XC; Louisiana Tumor Registry, School of Public Health, LSU Health Science Center-New Orleans, New Orleans, LA 70112, USA., Maluccio MA; School of Medicine, LSU Health Sciences Center-New Orleans, New Orleans, LA 70112, USA., Chu QD; Orlando Health Cancer Institute, Orlando, FL 32806, USA., Lyons JM 3rd; School of Medicine, LSU Health Sciences Center-New Orleans, New Orleans, LA 70112, USA.; Our Lady of the Lake Regional Medical Center, Baton Rouge, LA 70808, USA. |
| Abstrakt: |
Hepatocellular carcinoma (HCC) is a male-dominated disease. Currently, gender differences remain incompletely defined. Data from the state tumor registry were used to investigate differences in demographics, comorbidities, treatment patterns, and cancer-specific survival (HSS) among HCC patients according to gender. Additional analyses were performed to evaluate racial differences among women with HCC. 2627 patients with HCC were included; 498 (19%) were women. Women were mostly white (58%) or African American (39%)-only 3.8% were of another or unknown race. Women were older (65.1 vs. 61.3 years), more obese (33.7% vs. 24.2%), and diagnosed at an earlier stage (31.7% vs. 28.4%) than men. Women had a lower incidence of liver associated comorbidities (36.1% vs. 43%), and more often underwent liver-directed surgery (LDS; 27.5% vs. 22%). When controlling for LDS, no survival differences were observed between genders. African American women had similar HSS rates compared to white women (HR 1.14 (0.91,1.41), p = 0.239) despite having different residential and treatment geographical distributions. African American race and age >65 were predictive for worse HSS in men, but not in women. Overall, women with HCC undergo more treatment options-likely because of the earlier stage of the cancer and/or less severe underlying liver disease. However, when controlling for similar stages and treatments, HCC treatment outcomes were similar between men and women. African American race did not appear to influence outcomes among women with HCC as it did in men. |
